Breaking: USPTO releases Section 101 report

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Breaking: USPTO releases Section 101 report

Kathi Vidal
Kathi Vidal

The patent office report found that stakeholders were still divided over subject matter eligibility but broadly wanted clarity

The USPTO released a report on the state of subject matter eligibility today, June 28.

The office said stakeholders across the spectrum agreed that US patent eligibility law, which is set out in Section 101 under Title 35 of the US Code, needed to be clearer, more predictable and consistently applied. It also confirmed that different stakeholders maintained different views on the matter.

The USPTO published the document in response to a request from senators Thom Tillis, Chris Coons, Mazie Hirono, and Tom Cotton in March 2021.

The senators had asked the office to publish a request for information on the current state of patent eligibility jurisprudence in the US, evaluate the responses, and provide them with a detailed summary of its findings.

The report showed that certain stakeholders supported the current state of Section 101 law because it helped them fight abusive and costly litigation involving software patents they felt were too broad.

Some life sciences and patient advocacy organisations also supported the US’s 101 framework because it bolstered access to medical technologies, the report stated.

The USPTO said in its report that other stakeholders were critical of the law because they felt it inhibited investment in new technologies and companies, especially in life sciences.

Some start-ups and small and medium-sized enterprises argued that Section 101 law as it stood lowered access to private risk capital and undermined innovation.

“Though these results were not surprising, the USPTO will continue to solicit feedback from stakeholders, including through listening sessions,” the report stated.

The topic of Section 101 gained traction in the US after the Supreme Court issued its rulings on Mayo, Myriad and Alice between 2012 and 2014. These edicts made it harder for companies to obtain diagnostics, gene sequencing, software and other related patents.

The Supreme Court is now deciding whether to hear American Axle v Neapco. In that case, the Court of Appeals for the Federal Circuit invalidated American Axle’s drive shaft patent on the basis that it was directed towards a law of nature.

Counsel previously told Managing IP that they hoped the report would drive legislative change on Section 101.

more from across site and SHARED ros bottom lb

More from across our site

Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
While the UK sees heavy IP rankings movement, Germany’s new tiered UPC table signals a shift from early adoption to market maturity
In an exclusive interview, Bernard Ledeboer reveals how a Consolid-backed group of firms wants to expand across Europe, invest in AI and centralise operations to compete at the top tier
Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Gift this article